

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q86664

Graham Edmund KELLY

Appln. No.: 10/530,176

Group Art Unit: 4173

Confirmation No.: 8060

Examiner: Benjamin J PACKARD

Filed: April 4, 2005

For: COMBINATION CHEMOTHERAPY COMPOSITIONS AND METHODS

**RESPONSE TO RESTRICTION AND ELECTION OF SPECIES REQUIREMENTS**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This responds to the Restriction and Election of Species Requirement, dated

November 29, 2007.

In response to the Restriction Requirement, Applicant elects Group I, claims 1-4, 6-13 and 23-25 for examination. This election is made without traverse.

In response to the Election of Species Requirement, Applicant elects as follows:

A. As an isoflavoid compound of formula (I) of claim 1: compound 12 (dehydroequol), as disclosed on page 12 of the specification.

B. As a cancer/tumor to be treated: ovarian cancer.

C. As a chemotherapeutic agent: cisplatin.

RESPONSE TO RESTRICTION AND ELECTION OF SPECIES REQUIREMENTS

U.S. Application No.: 10/530,176

Attorney Docket No. Q86664


All of the claims, i.e., claims 1-4, 6-13 and 23-25, of the elected Group read on the elected species.

Applicant submits that if any of the elected claims is found to be allowable, claims dependent therefrom should similarly be considered allowable in the same application.

Applicant reserves the right to file a Divisional Application directed to non-elected claims 15, 16, 17, and 19-21.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

  
Susan J. Mack  
Registration No. 30,951

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

Date: May 29, 2008